United States Intravenous Iron Drugs Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The Global Intravenous Iron Drugs Market is expected to grow at a CAGR of 8.1% during the forecast period 2024-2031

Key Development:

United States: Recent Industry Developments

✅ In September 2025, Sandoz launched an affordable iron sucrose injection in the U.S., expanding its portfolio of high-quality injectable iron therapies. The product is now available nationwide, strengthening the U.S. supply of injectable iron sucrose.

✅ In August 2025, Viatris received FDA approval for its first generic iron sucrose injection, offering 50 mg, 100 mg, and 200 mg single-dose vials. This approval enhances access to iron deficiency anemia treatment for over 5 million U.S. patients.

Japan: Recent Industry Developments

✅ In April 2025, STX concluded a licensing agreement in Japan for ACCRUFeR® (ferric maltol), a novel oral iron therapy. This partnership aims to provide an effective treatment option for patients with iron deficiency anemia.

✅ In March 2025, Ono Pharmaceutical entered into an exclusive license agreement with Ionis Pharmaceuticals for sapablursen, a treatment designed to increase hepcidin production. The collaboration focuses on addressing iron homeostasis in blood diseases.

✅ In May 2024, a large-scale retrospective study in Japan compared prescription patterns between oral iron, saccharated ferric oxide, and ferric carboxymaltose (FCM) among over 360,000 treatment periods. The study highlighted FCM's effectiveness, suggesting shifts in clinical practice.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/intravenous-iron-drugs-market?sb

Intravenous iron drugs are formulations administered directly into the bloodstream to treat iron deficiency and anemia when oral iron is ineffective or unsuitable. They rapidly replenish iron stores, improve hemoglobin levels, and support red blood cell production, especially in patients with chronic kidney disease, cancer, or gastrointestinal disorders.

Recent Mergers and acquisitions:

United States: Recent M&A Activity

✅ In May 2025, Biocon acquired over 20 biosimilar assets from Viatris, including key oncology and autoimmune therapies. This acquisition strengthens Biocon's position in the global biosimilars market and expands its reach in over 70 countries.

✅ In June 2025, Sun Pharma completed the acquisition of the remaining 21.5% stake in Taro Pharmaceuticals for USD 347.73 million. This move consolidates Sun Pharma's ownership and enhances its dermatology portfolio.

✅ In August 2024, Pharmacosmos announced a merger with G1 Therapeutics in a transaction valued at USD 405 million. This strategic move aims to enhance Pharmacosmos's resources and expertise in hematology, particularly in the commercialization of Monoferric (ferric derisomaltose) Injection.

Japan: Recent M&A Activity

✅ In May 2025, Mitsubishi Power partnered with Chiyoda Corporation to integrate large-scale electrolyzers with offshore wind projects. (Note: This is more of a strategic partnership impacting iron therapy-related energy needs in production)

Key Players:

=> Allergan, Inc., Daiichi Sankyo Company, Ltd., Rockwell Medical Technologies, Inc., AMAG Pharmaceuticals. Inc., Sanofi, Fresenius Medical Care AG & Co., Vifor Pharma Management Ltd., Pharmacosmos A/S, Shield Therapeutics Plc, and American Regent. Inc. among others.

Growth Forecast Projected:

The Global Intravenous Iron Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Intravenous Iron Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=intravenous-iron-drugs-market

Key Segments:

➥ By Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Ferric Gluconate
➥ By Application: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer
➥ By Distribution Channel: Hospital Pharmacy, Pharmacy Stores, Others

Regional Analysis for Intravenous Iron Drugs Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Intravenous Iron Drugs producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Intravenous Iron Drugs revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/intravenous-iron-drugs-market?sb

FAQ

Q: What is the growth rate of the Intravenous Iron Drugs Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 8.1% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.